微芯生物

688321 SSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

13.0B ($1.9B)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

658.0M

Net Income

-115.0M

Gross Margin

N/A

Op. Margin

-27.2%

Net Margin

-17.5%

ROE

-7.3%

ROA

-3.5%

D/E

1.06

Dividend Yield

N/A

EPS

-0.28

Current Ratio

2.40

Price History

Company Info

Industry	C27医药制造业
Market Segment	STAR Market
Currency	CNY
Fiscal Year	2024

Business Overview

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-mol...

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 微芯生物

Ticker	688321
Exchange	SSE
Sector	证监会行业分类
Industry	C27医药制造业